FII stance, progress of monsoon, crude oil and rupee movement are likely to dictate the trend.
.jpg)
Markets ended lower on profit taking ahead of June F&O expiry.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
Nutritionist Rujuta Diwekar's approach to nutrition is driven by her grandmother.
'There are different kinds of risk.' 'It is a very powerful value. Your ability to de-risk the risk is also as important for risk taking.'
South-east Asian countries are emerging as preferable destination for India's pharma companies to expand their business as they share similar patient population and disease profile and moreover, have a conducive environment for their operations like easy market approach without any regulatory uncertainty, the survey of Indian pharma firms highlighted.
The Sensex ended lower on unfavourable cues.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
The 30-share Sensex ended higher by 31 points at 26,591 and the 50-share Nifty gained 10 points at 8,061.
Dilip Shanghvi has never tried to be everything to everybody.
Ranbaxy did its maiden public issue in 1973.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances